These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 31949293)
1. RGD-hirudin-based low molecular weight peptide prevents blood coagulation via subcutaneous injection. Li YR; Huang YN; Zhao B; Wu MF; Li TY; Zhang YL; Chen D; Yu M; Mo W Acta Pharmacol Sin; 2020 Jun; 41(6):753-762. PubMed ID: 31949293 [TBL] [Abstract][Full Text] [Related]
2. A novel hirudin derivative inhibiting thrombin without bleeding for subcutaneous injection. Zhao B; Zhang Y; Huang Y; Yu J; Li Y; Wang Q; Ma Y; Song HY; Yu M; Mo W Thromb Haemost; 2017 Jan; 117(1):44-56. PubMed ID: 27904902 [TBL] [Abstract][Full Text] [Related]
3. Structural basis of RGD-hirudin binding to thrombin: Tyr3 and five C-terminal residues are crucial for inhibiting thrombin activity. Huang Y; Zhang Y; Zhao B; Xu Q; Zhou X; Song H; Yu M; Mo W BMC Struct Biol; 2014 Dec; 14():26. PubMed ID: 25526801 [TBL] [Abstract][Full Text] [Related]
4. A novel oncotherapy strategy: Direct thrombin inhibitors suppress progression, dissemination and spontaneous metastasis in non-small cell lung cancer. Zhao B; Wu M; Hu Z; Wang T; Yu J; Ma Y; Wang Q; Zhang Y; Chen D; Li T; Li Y; Yu M; Wang H; Mo W Br J Pharmacol; 2022 Nov; 179(22):5056-5073. PubMed ID: 33481255 [TBL] [Abstract][Full Text] [Related]
5. A novel hirudin derivative characterized with anti-platelet aggregations and thrombin inhibition. Mo W; Zhang YL; Chen HS; Wang LS; Song HY J Thromb Thrombolysis; 2009 Aug; 28(2):230-7. PubMed ID: 18998199 [TBL] [Abstract][Full Text] [Related]
6. The antithrombotic effect of a novel hirudin derivative after reconstruction of carotid artery in rabbits. Lu WF; Mo W; Liu Z; Fu WG; Guo DQ; Wang YQ; Song HY Thromb Res; 2010 Oct; 126(4):e339-43. PubMed ID: 20483158 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of coagulation and thrombin-induced platelet activities by a synthetic dodecapeptide modeled on the carboxy-terminus of hirudin. Jakubowski JA; Maraganore JM Blood; 1990 Jan; 75(2):399-406. PubMed ID: 2294999 [TBL] [Abstract][Full Text] [Related]
8. A recombinant hirudin (IK-HIR02) in healthy volunteers. I. Effects on coagulation parameters and bleeding time. Schenk JF; Glusa E; Radziwon P; Butti A; Markwardt F; Breddin HK Haemostasis; 1996; 26(3):140-9. PubMed ID: 8738588 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, effect on clotting tests and assessment of the immunogenic potential of hirudin after a single subcutaneous or intravenous bolus administration in man. Bichler J; Siebeck M; Fichtl B; Fritz H Haemostasis; 1991; 21 Suppl 1():137-41. PubMed ID: 1716603 [TBL] [Abstract][Full Text] [Related]
10. Distinct features of bivalent direct thrombin inhibitors, hirudin and bivalirudin, revealed by clot waveform analysis and enzyme kinetics in coagulation assays. Wakui M; Fujimori Y; Nakamura S; Kondo Y; Kuroda Y; Oka S; Nakagawa T; Katagiri H; Murata M J Clin Pathol; 2019 Dec; 72(12):817-824. PubMed ID: 31366633 [TBL] [Abstract][Full Text] [Related]
11. Laboratory assays for the evaluation of recombinant hirudin. Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197 [TBL] [Abstract][Full Text] [Related]
12. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban. Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603 [TBL] [Abstract][Full Text] [Related]
13. The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma. Boström SL; Hansson GF; Sarich TC; Wolzt M Thromb Res; 2004; 113(1):85-91. PubMed ID: 15081569 [TBL] [Abstract][Full Text] [Related]
14. Efficient targeted anticoagulant with active RGD motif. Bi Q; Zhou X; Cen X; Qu H; Luo J; Huang Y; Zhu S Thromb Res; 2007; 120(4):541-7. PubMed ID: 17222892 [TBL] [Abstract][Full Text] [Related]
16. Effective use of BCH-2763, a new potent injectable direct thrombin inhibitor, in combination with tissue plasminogen activator (tPA) in a rat arterial thrombolysis model. Deschênes I; Finkle CD; Winocour PD Thromb Haemost; 1998 Jul; 80(1):186-91. PubMed ID: 9684808 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of hirudin in man after single subcutaneous and intravenous bolus administration. Bichler J; Fichtl B; Siebeck M; Fritz H Arzneimittelforschung; 1988 May; 38(5):704-10. PubMed ID: 3415713 [TBL] [Abstract][Full Text] [Related]
18. [Comparative in vitro study of anticoagulant activity of RA36 DNA aptamer in human, rabbit, and rat blood plasma]. Savchik EIu; Kalinina TB; Drozd NN; Makarov VA; Zav'ialova EG; Lapsheva EN; Babiĭ AV; Mudrik NN; Pavlova GV; Golovin AV; Kopylov AM Eksp Klin Farmakol; 2012; 75(11):13-8. PubMed ID: 23323327 [TBL] [Abstract][Full Text] [Related]
19. Chimeric antithrombin peptide. Characterization of an Arg-Gly-Asp (RGD)- and hirudin carboxyl terminus-containing synthetic peptides. Church FC; Phillips JE; Woods JL J Biol Chem; 1991 Jun; 266(18):11975-9. PubMed ID: 2050691 [TBL] [Abstract][Full Text] [Related]
20. Antithrombin effects of native and recombinant hirudins. Markwardt F; Stürzebecher J; Glusa E Biomed Biochim Acta; 1990; 49(5):399-404. PubMed ID: 2271010 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]